Publication:
Immunological and senescence biomarker profiles in patients after spontaneous clearance of hepatitis C virus: gender implications for long-term health risk

dc.contributor.authorMartín-Escolano, Rubén
dc.contributor.authorVidal-Alcántara, Erick Joan
dc.contributor.authorCrespo, Javier
dc.contributor.authorRyan, Pablo
dc.contributor.authorReal, Luis Miguel
dc.contributor.authorLazo-Álvarez, Juan Ignacio
dc.contributor.authorCabezas-González, Joaquín
dc.contributor.authorMacías, Juan
dc.contributor.authorArias-Loste, María Teresa
dc.contributor.authorCuevas, Guillermo
dc.contributor.authorVirseda-Berdices, Ana
dc.contributor.authorBriz, Veronica
dc.contributor.authorResino, Salvador
dc.contributor.authorJimenez-Sousa, Maria Angeles
dc.contributor.authorFernandez-Rodriguez, Amanda
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderFundación Universidad Alfonso X el Sabio
dc.contributor.funderFundación Banco Santander
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
dc.contributor.funderUnión Europea. Comisión Europea. NextGenerationEU
dc.contributor.funderAgencia Estatal de Investigación (España)
dc.date.accessioned2023-11-27T10:00:32Z
dc.date.available2023-11-27T10:00:32Z
dc.date.issued2023-11-17
dc.description.abstractBackground: About 25% of patients with acute hepatitis C virus (HCV) infection show spontaneous clearance within the first six months of infection but may remain at risk of inflammaging, aging, and liver and non-liver disease complications. This study evaluated the differences in the plasma levels of immune checkpoints (ICs) and senescence-associated secretory phenotype (SASP) biomarkers between patients who had spontaneously eliminated HCV infection (SC group) and individuals without evidence of HCV infection (C group). Methods: We performed a multicenter retrospective study of 56 individuals: 32 in the SC and 24 in the C groups. ICs and SASP proteins were analyzed using a Luminex 200TM analyzer. The statistical analysis used Generalized Linear Models with gamma distribution (log-link) adjusted by significant variables and sex. Results: 13 ICs (BTLA, CD137(4-1BB), CD27, CD28, CD80, GITR, HVEM, IDO, LAG-3, PD-1, PD-L1, PD-L2, and TIM-3) and 13 SASP proteins (EGF, Eotaxin, IL-1alpha, IL-1RA, IL-8, IL-13, IL-18, IP-10, SDF-1alpha, HGF, beta-NGF, PLGF-1, and SCF) were significantly higher in SC group after approximately more than two years of HCV clearance. After stratifying by sex, differences remained significant for males, which showed higher levels for 13 ICs and 4 SASP proteins in SC. While only PD-L2 was significantly higher in SC women, and no differences in SASP were found. Conclusions: Higher plasma levels of different IC and SASP proteins were found in individuals after more than two years of HCV clearance, mainly in men. Alterations in these molecules might be associated with an increased risk of developing liver and non-hepatic diseases.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant number CP14/0010) to AFR), Fundación Universidad Alfonso X el Sabio (FUAX) – Santander (grant number 1.010.932 to AFR) and by PID2021–126781OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. The study was also funded by the CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea–Next‑GenerationEU (CB21/13/00044, CB21/13/00118, and GVC16/EHD/4). M.A.J.-S. is Miguel Servet researcher supported and funded by ISCIII (grant numbers CP17CIII/00007). RME is Juan de la Cierva researcher supported and fnanced by MICINN of Spain (FJC2020-042865-I).es_ES
dc.format.number1es_ES
dc.format.page62es_ES
dc.format.volume20es_ES
dc.identifier.citationImmun Ageing. 2023 Nov 17;20(1):62.es_ES
dc.identifier.doi10.1186/s12979-023-00387-zes_ES
dc.identifier.issn1742-4933es_ES
dc.identifier.journalImmunity & ageing : I & Aes_ES
dc.identifier.pubmedID37978401es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16732
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC)
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2021–126781OB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/FJC2020-042865-Ies_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CP14/0010es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CP17CIII/00007es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CB21/13/00044es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CB21/13/00118es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/GVC16/EHD/4es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s12979-023-00387-zes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectBiomarkerses_ES
dc.subjectHCVes_ES
dc.subjectImmune checkpoint proteinses_ES
dc.subjectSASP proteinses_ES
dc.subjectSpontaneous clearancees_ES
dc.titleImmunological and senescence biomarker profiles in patients after spontaneous clearance of hepatitis C virus: gender implications for long-term health riskes_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication32640c9c-427d-403a-9a9d-bc40351fb486
relation.isAuthorOfPublicationfecfe47e-d32a-49a8-bbec-5b14f590d477
relation.isAuthorOfPublicationd18c653c-226a-4a2f-9a10-e2b5af9c3b33
relation.isAuthorOfPublication727b9535-a250-4e80-969f-c5d33f92246d
relation.isAuthorOfPublication89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isAuthorOfPublication2bf7faec-7f00-44ba-9494-efb396305551
relation.isAuthorOfPublication6a32a4a3-2d81-43c5-8295-48346efbf498
relation.isAuthorOfPublication.latestForDiscovery32640c9c-427d-403a-9a9d-bc40351fb486
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationa6ae0db5-9c7b-4544-b685-008673740ac3
relation.isFunderOfPublication943a5029-a663-403e-84ea-b4cad184a4ca
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublication0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72
relation.isFunderOfPublication54f29c6e-1163-4239-8d1d-a0f297ca06e6
relation.isFunderOfPublication54733407-1d78-4c44-bf4c-8c8a7592aa4b
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication4fe896aa-347b-437b-a45b-95f4b60d9fd3
relation.isPublisherOfPublication.latestForDiscovery4fe896aa-347b-437b-a45b-95f4b60d9fd3

Files

Original bundle

Now showing 1 - 5 of 12
Loading...
Thumbnail Image
Name:
ImmunologicalSenescenceBiomarkerProfiles_2023.pdf
Size:
2.43 MB
Format:
Adobe Portable Document Format
Description:
Articulo
Loading...
Thumbnail Image
Name:
Supplementary1_ImmunologicalSenescenceBiomarkerProfiles_2023.pdf
Size:
657.62 KB
Format:
Adobe Portable Document Format
Description:
supplementary material 1
Loading...
Thumbnail Image
Name:
Supplementary2_ImmunologicalSenescenceBiomarkerProfiles_2023.pdf
Size:
470.99 KB
Format:
Adobe Portable Document Format
Description:
supplementary material 2
Loading...
Thumbnail Image
Name:
Supplementary3_ImmunologicalSenescenceBiomarkerProfiles_2023.pdf
Size:
367.72 KB
Format:
Adobe Portable Document Format
Description:
supplementary material 3
Loading...
Thumbnail Image
Name:
Supplementary4_ImmunologicalSenescenceBiomarkerProfiles_2023.pdf
Size:
466.36 KB
Format:
Adobe Portable Document Format
Description:
supplementary material 4